# Candel Therapeutics, Inc.: overview CADL · Nasdaq · CIK 1841387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cadl.md) · [Financials](/companies/cadl/financials.md) · [Filings](/companies/cadl/filings.md) · [Insiders](/companies/cadl/insiders.md) Latest reported revenue: [$31.0k](/filings/0000950170-24-037637.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 28, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-24-037637). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.33)](/filings/0001193125-25-279086.md) | not reported | [0.13](/filings/0001193125-26-222904.md) | [(0.09)](/filings/0001193125-26-347980.md) | [(0.21)](/filings/0001193125-25-279086.md) | not reported | [(0.14)](/filings/0001193125-26-222904.md) | [(0.52)](/filings/0001193125-26-347980.md) | | Free cash flow | $m | [(6.6) d](/filings/0001193125-25-279086.md) | [(5.8) d](/filings/0001193125-26-103134.md) | [(8.6)](/filings/0001193125-26-222904.md) | [(8.9) d](/filings/0001193125-26-347980.md) | [(10.4) d](/filings/0001193125-25-279086.md) | [(11.0) d](/filings/0001193125-26-103134.md) | [(18.7)](/filings/0001193125-26-222904.md) | [(17.3) d](/filings/0001193125-26-347980.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0000950170-23-010760.md) | [0.1](/filings/0000950170-24-037637.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(20580.8%)](/filings/0000950170-23-010760.md) | [(27777.6%)](/filings/0000950170-24-037637.md) | not reported | not reported | not reported | | Net margin | % | [(28899.2%)](/filings/0000950170-23-010760.md) | [(15035.2%)](/filings/0000950170-24-037637.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.91)](/filings/0000950170-23-010760.md) | [(0.65)](/filings/0000950170-24-037637.md) | [(1.31)](/filings/0000950170-25-038803.md) | [(1.74)](/filings/0001193125-26-103134.md) | [(0.72)](/filings/0001193125-26-103134.md) | | Free cash flow | $m | [(24.1)](/filings/0000950170-23-010760.md) | [(32.7)](/filings/0000950170-24-037637.md) | [(34.7)](/filings/0000950170-25-038803.md) | [(27.0)](/filings/0001193125-26-103134.md) | [(38.9)](/filings/0001193125-26-103134.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cadl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $113.2m | 10,990,535 | | Added +3,518 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $66.1m | 6,422,018 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $51.2m | 4,969,040 | | Added +1,859,998 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $36.6m | 3,549,823 | | Added +2,731,265 | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $36.0m | 3,497,948 | | Unchanged | | [Portolan Capital Management, LLC](/funds/1350290.md) | 2026-06-30 | $36.0m | 3,490,398 | | Added +596,073 | | [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $34.0m | 3,303,686 | | Added +407,098 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $27.7m | 2,694,040 | | Added +231,283 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $16.2m | 1,571,021 | | Added +535,586 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.3m | 1,093,905 | | Added +33,819 | ## Recent filings [All 413 filings](/companies/cadl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-10 | 12:16 ET | [8-K](/filings/0001193125-26-387310.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-387310 | | 2026-09-09 | 20:50 ET | [8-K](/filings/0001193125-26-386561.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-386561 | | 2026-08-13 | 12:30 ET | [10-Q](/filings/0001193125-26-347980.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347980 | | 2026-08-13 | 12:15 ET | [8-K](/filings/0001193125-26-347957.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347957 | | 2026-06-24 | 20:24 ET | [8-K](/filings/0001841387-26-000009.md) | 5.07 Shareholder vote results | 0001841387-26-000009 | | 2026-06-16 | 20:23 ET | [8-K](/filings/0001841387-26-000007.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001841387-26-000007 | | 2026-05-15 | 20:13 ET | [8-K](/filings/0001193125-26-226751.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-226751 | | 2026-05-14 | 12:30 ET | [10-Q](/filings/0001193125-26-222904.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222904 | | 2026-05-14 | 12:15 ET | [8-K](/filings/0001193125-26-222892.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-222892 | | 2026-04-29 | 20:05 ET | [DEF 14A](/filings/0001193125-26-191506.md) | Proxy statement, period 2026-06-23 | 0001193125-26-191506 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-103134.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1841387 - Tickers: CADL - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.